Regenxbio (RGNX) Misses Q1 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
UPDATE: Regenxbio (RGNX) Reports Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for Treatment of Wet AMD
May 7, 2019 5:07 PM EDT(Updated - May 7, 2019 5:07 PM EDT)
REGENXBIO Inc. (NASDAQ: RGNX) today an update to its Phase I/IIa trial of RGX-314 for the treatment of wet age-related macular degeneration (wet AMD), since its previously reported interim results. The interim data update announced today includes safety assessments for all subjects enrolled as of April 18, 2019, and new assessments of efficacy at one year after a single administration of RGX-314 for Cohort 3 (6 x 10^10 GC/eye).
As of April 18, 2019, 33 subjects across five dose cohorts have been treated in the Phase I/IIa trial... More